NKTR FY 2018 Earnings Report — Nektar Therapeutics Revenue & Financial Results | Market Cap Arena

Nektar TherapeuticsNKTR

FY 2018 Earnings

Reported March 1, 2019

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	FY 2018	Prior Q	FY 2017	QoQ Change	YoY Change
Revenue	$1.2B	—	$308M	—	287.8%
Op. Income	$688M	—	-$60M	—	1253.4%
Gross Margin	98.0%	—	90.1%	—	7.9pp
Net Margin	57.1%	—	-31.4%	—	88.5pp
EPS (Diluted)	$56.70	—	$-9.30	—	709.7%
Free Cash Flow	$704M	—	-$90M	—	881.4%

Revenue Flow

Item	Amount
REVENUE	$1.2B
Cost of Revenue	$24M
GROSS PROFIT	$1.2B
R&D Expenses	$400M
Selling & Marketing	$0
General & Administrative	$81M
SG&A Expenses	$81M
Other Expenses	$0
Operating Expenses	$481M
Cost & Expenses	$505M
OPERATING INCOME	$688M
Interest Income	$38M
Interest Expense	$43M
Other Income/Expenses	-$5M
INCOME BEFORE TAX	$683M
Income Tax Expense	$1M
Net Income from Continuing Ops	$681M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$681M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$681M
D&A	$9M
EBIT	$726M
EBITDA	$734M
EPS	$57
EPS Diluted	$57

Income Statement

Item	Amount
REVENUE	$1.2B
Cost of Revenue	$24M
GROSS PROFIT	$1.2B
R&D Expenses	$400M
Selling & Marketing	$0
General & Administrative	$81M
SG&A Expenses	$81M
Other Expenses	$0
Operating Expenses	$481M
Cost & Expenses	$505M
OPERATING INCOME	$688M
Interest Income	$38M
Interest Expense	$43M
Other Income/Expenses	-$5M
INCOME BEFORE TAX	$683M
Income Tax Expense	$1M
Net Income from Continuing Ops	$681M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$681M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$681M
D&A	$9M
EBIT	$726M
EBITDA	$734M
EPS	$57
EPS Diluted	$57

Cash Flow Statement

Item	Amount
Net Income	$681M
Depreciation & Amortization	$11M
Stock-Based Compensation	$88M
Deferred Income Tax	$0
Other Non-Cash Items	-$23M
Change in Working Capital	-$39M
OPERATING CASH FLOW	$718M
Capital Expenditure	-$14M
Acquisitions (Net)	$3M
Purchases of Investments	-$2.3B
Sales/Maturities of Investments	$903M
Other Investing Activities	$3M
NET CASH FROM INVESTING	-$1.4B
Net Debt Issuance	$0
Common Stock Repurchased	$0
Common Dividends Paid	$0
Other Financing Activities	$62M
NET CASH FROM FINANCING	$852M
FREE CASH FLOW	$704M
Net Change in Cash	$190M

Balance Sheet

Item	Amount
Cash & Equivalents	$195M
Short-Term Investments	$1.1B
Net Receivables	$43M
Inventory	$11M
Other Current Assets	$21M
TOTAL CURRENT ASSETS	$1.4B
PP&E (Net)	$49M
Goodwill	$77M
Intangible Assets	$0
Long-Term Investments	$583M
Tax Assets	$0
Other Non-Current Assets	$4M
TOTAL NON-CURRENT ASSETS	$712M
TOTAL ASSETS	$2.2B
Account Payables	$6M
Short-Term Debt	$0
Deferred Revenue	$14M
Other Current Liabilities	$52M
TOTAL CURRENT LIABILITIES	$82M
Long-Term Debt	$247M
Deferred Revenue NC	$11M
Deferred Tax Liabilities	$0
Other Non-Current Liabilities	$93M
TOTAL NON-CURRENT LIABILITIES	$351M
TOTAL LIABILITIES	$433M
Common Stock	$17.0K
Additional Paid-In Capital	$3.1B
Retained Earnings	-$1.4B
Treasury Stock	$0
Accum. Other Comp. Income	-$6M
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	$1.7B
Minority Interest	$0
TOTAL EQUITY	$1.7B
TOTAL LIABILITIES & EQUITY	$2.2B
Total Debt	$247M
Net Debt	$52M